M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm

Interventions: Other: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Other: Waiting List

First Posted Date: 2019-04-25

Last Posted Date: 2024-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03927885

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery

Not Applicable

Completed

Conditions: Glioblastoma

Interventions: Procedure: Computed Tomography
Other: Fluciclovine F18
Procedure: Positron Emission Tomography

First Posted Date: 2019-04-24

Last Posted Date: 2024-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT03926507

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Phase 1

Active, not recruiting

Conditions: Neoplasms, Glandular and Epithelial
Central Nervous System Diseases
Neuroectodermal Tumors, Primitive
Cerebellar Neoplasms
Neoplasm Metastases
Neoplasms, Germ Cell and Embryonal
Central Nervous System Neoplasms, Primary
Neoplasms by Site
Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Neuroectodermal Tumors

Interventions: Biological: G207

First Posted Date: 2019-04-11

Last Posted Date: 2024-08-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT03911388

Locations: 🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Children's of Alabama, Birmingham, Alabama, United States

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Phase 1

Recruiting

Conditions: Recurrent Glioblastoma
Recurrent Gliosarcoma
Recurrent Malignant Glioma
IDH1 wt Allele
Recurrent Anaplastic Astrocytoma

Interventions: Biological: Oncolytic Adenovirus Ad5-DNX-2401
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2019-04-01

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT03896568

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

Not Applicable

Active, not recruiting

Conditions: Stage IIIA Hepatocellular Carcinoma AJCC v8
Stage III Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8
Unresectable Hepatocellular Carcinoma
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IIIB Hepatocellular Carcinoma AJCC v8
Stage IVA Hepatocellular Carcinoma AJCC v8

Interventions: Procedure: Computed Tomography
Other: Hepatobiliary Iminodiacetic Acid Scan
Procedure: Single Photon Emission Computed Tomography
Radiation: Yttrium Y 90 Glass Microspheres
Procedure: Yttrium-90 Microsphere Radioembolization

First Posted Date: 2019-04-01

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT03896646

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 1

Recruiting

Conditions: Blasts 10-19 Percent of Bone Marrow Nucleated Cells
Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
High Risk Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic Leukemia
Recurrent High Risk Myelodysplastic Syndrome
Refractory Chronic Myelomonocytic Leukemia
Refractory High Risk Myelodysplastic Syndrome

Interventions: Drug: Liposome-encapsulated Daunorubicin-Cytarabine

First Posted Date: 2019-03-29

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT03896269

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Early Metabolic Resuscitation for Septic Shock

Phase 2

Terminated

Conditions: Severe Sepsis
Septic Shock
Multiple Organ Failure

Interventions: Other: Best Practice
Dietary Supplement: early metabolic resuscitation

First Posted Date: 2019-03-29

Last Posted Date: 2024-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT03895853

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers

Not Applicable

Recruiting

Conditions: Thyroid Gland Medullary Carcinoma

Interventions: Other: Decision Aid
Other: Questionnaire Administration

First Posted Date: 2019-03-27

Last Posted Date: 2024-07-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT03892993

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers

Active, not recruiting

Conditions: Head and Neck Carcinoma

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-03-25

Last Posted Date: 2024-10-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 125

Registration Number: NCT03888651

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

Phase 1

Withdrawn

Conditions: Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma

Interventions: Drug: Trabectedin
Drug: Venetoclax

First Posted Date: 2019-03-21

Last Posted Date: 2023-09-25

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03884972

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy